{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:24:07Z","timestamp":1790425447319,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"vor","delay-in-days":232,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007150","name":"United Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bayer Pharma AG"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CSL Behring"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/j.rmcr.2019.100927","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T16:01:14Z","timestamp":1566489674000},"page":"100927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion"],"prefix":"10.1016","volume":"28","author":[{"given":"Khodr","family":"Tello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Beutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timm","family":"Greulich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus Franz","family":"Vogelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Jonas","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kuhnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"B\u00f6selt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Idzko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Buhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Rembert","family":"Koczulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2019.100927_bib1","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1067\/mai.2003.1449","article-title":"A comprehensive study of the direct and indirect costs of adult asthma","volume":"111","author":"Cisternas","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmcr.2019.100927_bib2","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/all.12275","article-title":"EAACI position statement on asthma exacerbations and severe asthma","volume":"68","author":"Custovic","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.rmcr.2019.100927_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1081-1206(10)60200-1","article-title":"Risk factors for death in adults with severe asthma","volume":"101","author":"Omachi","year":"2008","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmcr.2019.100927_bib4","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2019.100927_bib5","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2019.100927_bib6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"The Lancet"},{"key":"10.1016\/j.rmcr.2019.100927_bib7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2019.100927_bib8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmcr.2019.100927_bib9","unstructured":"FDA approves Nucala to treat severe asthma, n.d, FDA News Release. U.S. Food and Drug Administration."},{"key":"10.1016\/j.rmcr.2019.100927_bib10","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2147\/TCRM.S149775","article-title":"Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty","volume":"13","author":"Menzella","year":"2017","journal-title":"TCRM"},{"key":"10.1016\/j.rmcr.2019.100927_bib11","first-page":"100875","article-title":"Successful treatment with mepolizumab in a case of allergic bronchopulmonary aspergillosis complicated with nontuberculous mycobacterial infection","volume":"28","author":"Tsubouchi","year":"2019","journal-title":"Respir. Med. Case Rep."},{"key":"10.1016\/j.rmcr.2019.100927_bib12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jaci.2013.11.026","article-title":"Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis","volume":"133","author":"Haldar","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmcr.2019.100927_bib13","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1136\/thoraxjnl-2014-205581","article-title":"Characterisation of an OCS-dependent severe asthma population treated with mepolizumab","volume":"69","author":"Prazma","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.rmcr.2019.100927_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaci.2015.05.037","article-title":"Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia","volume":"137","author":"Smith","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmcr.2019.100927_bib15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/cea.12695","article-title":"Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma","volume":"46","author":"Sehmi","year":"2016","journal-title":"Clin. Exp. Allergy"}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007119302187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007119302187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T21:16:33Z","timestamp":1590095793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007119302187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":15,"alternative-id":["S2213007119302187"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2019.100927","relation":{},"ISSN":["2213-0071"],"issn-type":[{"value":"2213-0071","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2019.100927","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100927"}}